The explosion of interest in CBD has left many consumers uncertain as to which mode of delivery will make them benefit the most from this cannabinoid. From tinctures, topicals, suppositories, edibles, oils and even clothing infused in CBD, the options are nearly endless. However, one company has worked with a team of scientists and published their findings after subjecting their research to a peer-review system to confirm that they had pioneered the best way so far for people to get more CBD into their bodies.
The body isn’t very good at absorbing CBD, so a lot of what is consumed is lost during the process of digestion. However, RESET Bioscience has flipped the script on CBD absorption by introducing a novel way to consume CBD.
The company teamed up with an Austin, Texas research facility called Sante Laboratories to document research about the absorption rates of nano-liposomes that are infused with pure CBD.
Nano-liposomes are suspensions of fatty acids or lipids. The product made using these nanoparticles is neither an oil nor a pill. Nevertheless, the research done shows that this delivery method improves CBD bioavailability and absorption by up to 80 percent when compared to the existing delivery methods.
The result of this superior method of delivery is that a consumer will feel better sooner and they will not need to take as much CBD to get the desired effects as they used to do when they were using products with a poorer absorption rate.
The research titled “Characterization and Pharmacokinetics of a Novel Nano-Liposome Delivery System of Cannabidiol” was led by Dr. Brian Sloat, PhD and the study was presented to the 2019 Cannabis Science Conference, a peer-reviewed forum.
Dr. Sloat, a pharmaceutical scientist, has decades of experience under his belt in studying drug formulation, manufacturing and delivery. He was also involved in developing anthrax vaccine prototypes and has published more than 20 papers on the subject of lipo-based nanoparticles.
The CBD industry has been rife with companies making what federal regulators like the FDA and FTC call “unsubstantiated claims” about their products. RESET Bioscience has decided to take a different route and prove, scientifically, that their products offer superior bioavailability when compared to others on the market.
Since many consumers have been drawn to CBD products because of the many health benefits attributed to this cannabinoid, RESET Bioscience is likely to have an edge over other companies that have not yet made public their investigations into what makes their products good.
Analysts feel that that CBD companies like HTC Extraction Systems (TSX.V: HTC) and IONIC Brands Corp. (CSE: IONC) (OTC: IONKF) now have the ball in their court to respond to the step taken by RESET Biosciences.
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.cbdwire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have a questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com
